-
Global Biotechnology & Pharmaceutical Markets1 month agoEurope’s CHMP endorses slew of new medicines, including new offerings from Novo and AZ
The CHMP recommendation for Novo's next gen hemophilia A treatment was one of several noteworthy endorsements made by the EU agency this week.
-
Global Biotechnology & Pharmaceutical Markets1 month agoMPs seek probe into UK-US pharma deal’s impact on NHS
The chairs of six UK parliamentary committees have asked the National Audit Office to investigate the UK-US pharma deal and its impact on the NHS.
-
Global Biotechnology & Pharmaceutical Markets1 month ago
Fierce Pharma Asia—China deals safe from COINS?; Key WCLC data; Legend’s new CEO
Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports. Akeso and Summit's ivonescimab, B7-H3 ADCs...
-
Global Biotechnology & Pharmaceutical Markets1 month agoSTAT+: England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
A breast cancer drug from AstraZeneca will now be available in England after a pricing deal was reached, in part a result of the U.S.-U.K. pharma...
-
Global Biotechnology & Pharmaceutical Markets1 month ago
SK pens $315M pact with fellow South Korean company for Parkinson’s prospect
SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal with a fellow South Korean drug...
-
Global Biotechnology & Pharmaceutical Markets1 month ago
How Learning Systems Move Pharma Marketing Beyond the Box Score
It’s time for pharma marketers to up their ask of AI—not just making better decisions, but building smarter systems that learn from every outcome.
-
Global Biotechnology & Pharmaceutical Markets1 month agoFDA signals tighter scrutiny of early-stage data from China
BIOCENTURY | POLITICS, POLICY & LAWFDA SIGNALS TIGHTER SCRUTINY OF EARLY-STAGE DATA FROM CHINAU.S. agency acknowledges concerns, steers clear of outright ban on China data advocated...
-
Global Biotechnology & Pharmaceutical Markets1 month agoWCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability...
-
Global Biotechnology & Pharmaceutical Markets1 month agoEnsuring safety and accountability in China’s biomedical translation system
Nature Biotechnology, Published online: 15 September 2026; doi:10.1038/s41587-026-03314-xChina’s Decree 818 aims to bring hospital-based cell, gene and individualized therapies into the clinic safely. Its success will...
-
Global Biotechnology & Pharmaceutical Markets1 month agoSTAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more
GSK has continued its drive to bulk up its pipeline, taking global rights to a multiple myeloma treatment developed in China
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
